Seeking Alpha

Glaring inconsistencies discovered in HeartWare trial PI interview: Northland

  • Northland Capital's Suraj Kalia says there are "glaring inconsistencies" between what HeartWare International (HTWR +0.8%) says about the final protocol for a destination therapy submission and what one of the principal investigators on the trial says.
  • Northland says Dr. Joseph Rogers expects to present data from the trial next year, but the company seems to say otherwise.
  • Rogers and the company also seem to disagree about whether or not data should be aggregated.
  • "How do you expect PI's to successfully 'defend' the trial, especially when they haven't been consulted about data analysis or presentation," Kalia asks.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector